Document:

Royalty Termination Agmt among Biovest, LV Administrative, and Valens U.S.

 Exhibit 10.20 
 ROYALTY TERMINATION AGREEMENT 
 THIS ROYALTY
TERMINATION AGREEMENT (this “Agreement”) is made as of November 17, 2010, by and between BIOVEST INTERNATIONAL, INC., a Delaware corporation (“Biovest”), on the one hand, and LV ADMINISTRATIVE SERVICES,
INC., a Delaware corporation, as administrative and collateral agent for the Lenders (the “Agent”), and VALENS U.S. SPV I, LLC (“Valens U.S.”), on the other hand. 

RECITALS 
 WHEREAS, on October 30, 2007, Biovest and Valens U.S. entered into a Note Purchase Agreement (the “October 2007 Purchase Agreement”), pursuant to which Valens U.S. purchased a
Secured Promissory Note in the original principal amount of $245,000.00 from Biovest; 
 WHEREAS, in
connection with the October 2007 Purchase Agreement, Biovest and Valens U.S. entered into a Royalty Agreement dated as of October 30, 2007 (the “October 2007 Royalty Agreement”), pursuant to which Biovest granted to Valens U.S.
a royalty equal to 0.92% of net sales and licensing revenue received by Biovest from any Biovest Biologic Products (the “October 2007 Royalty”); 

WHEREAS, on December 10, 2007, Biovest and Valens U.S. entered into a Note Purchase Agreement (the
“December 2007 Purchase Agreement”), pursuant to which Valens U.S. purchased a Secured Promissory Note in the original principal amount of $4,900,000.00 from Biovest; 

WHEREAS, in connection with the December 2007 Purchase Agreement, Biovest and Valens U.S. entered into a Royalty
Agreement dated as of December 10, 2007 (the “December 2007 Royalty Agreement” and together with the October 2007 Royalty Agreement, the “Royalty Agreement”), pursuant to which Biovest granted to Valens U.S. a
royalty equal to 4.04% (which, when aggregated with the October 2007 Royalty, equaled a total royalty of 4.96%) of net sales and licensing revenue received by Biovest from any Biovest Biologic Products (the “December 2007 Royalty”
and together with the October 2007 Royalty, the “Royalty”); 

WHEREAS, pursuant to that certain Term Loan and Security Agreement (the “Security
Agreement”) dated as of November 17, 2010, by and among Biovest, the Lenders party thereto and the Agent, the parties hereto, in consideration for the acceptance by certain of the Prepetition Lenders of the allowed secured claims
against Biovest as provided therein, have agreed, among other things, to (i) the termination of the Royalty Agreement and the Royalty and (ii) the granting to certain of the Lenders of a contingent payment equal to 6.25% of the gross
revenue received from the sale, licensing or other disposition of the BiovaxID® vaccine and Biovest Biologic
Products, pursuant to those certain Contingent Payment Agreements of even date herewith between Biovest and certain of the Lenders; and 
 WHEREAS, pursuant to the terms and conditions of the Security Agreement and the Confirmed Plan, the parties hereto hereby desire to terminate the Royalty Agreement and the Royalty effective as of
the date of this Agreement. 

  
 -1-

 NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 

1.        Capitalized terms used but not defined herein shall have the meanings
ascribed to them in the Security Agreement. 
 2.        The parties
hereto agree that the above Recitals are true and correct in all respects. 

3.        The parties hereto hereby consent to the termination of the Royalty
Agreement and the Royalty (and all of the rights and obligations created thereunder) effective as of the date of this Agreement. 
 4.        Each of Valens U.S. and the Agent hereby acknowledges and agrees that it shall have no claims of any nature whatsoever against Biovest as a result of the
termination of the Royalty Agreement and the Royalty. 
 5.        This
Agreement shall be binding upon the parties hereto and their respective successors and assigns. The parties hereto agree that this Agreement is fully and adequately supported by consideration, is fair and reasonable, and that they have had the
opportunity to discuss this matter with counsel of their choice. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall be deemed to constitute one agreement. It is
understood and agreed that if facsimile copies of this Agreement bearing facsimile signatures are exchanged between the parties hereto, such copies shall in all respects have the same weight, force and legal effect and shall be fully as valid,
binding, and enforceable as if such signed facsimile copies were original documents bearing original signature. 

6.        THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED, INTERPRETED AND
ENFORCED ACCORDING TO, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICT OF LAWS PROVISIONS THEREOF. ANY ACTION BROUGHT CONCERNING THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT SHALL BE BROUGHT ONLY IN THE STATE
COURTS OF NEW YORK OR IN THE FEDERAL COURTS LOCATED IN THE STATE OF NEW YORK. The prevailing party shall be entitled to recover from the other party its reasonable attorneys’ fees and costs. Wherever possible each provision of this
Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective to the extent of such
prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. 

[remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as
of the date first above written. 
  

			
	BIOVEST INTERNATIONAL, INC.
		
	By:	 	 /s/ David Moser

	Name:	 	David Moser
	Title:	 	Secretary

  

			
	LV ADMINISTRATIVE SERVICES, INC.
		
	By:	 	 /s/ Patrick Regan

	Name:	 	Patrick Regan

			
	Title:	 	Authorized Signatory

  

			
	VALENS U.S. SPV I, LLC
		
	By:	 	 /s/ Patrick Regan

	Name:	 	Patrick Regan

			
	Title:	 	Authorized SignatoryRoyalty Termination Agmt among Biovest, LV Administrative and the Lenders

 Exhibit 10.21 
 ROYALTY TERMINATION AGREEMENT 
 THIS ROYALTY
TERMINATION AGREEMENT (this “Agreement”) is made as of November 17, 2010, by and among AUTOVAXID, INC., a Florida corporation (“AutovaxID”) and BIOVEST INTERNATIONAL, INC., a Delaware corporation
(“Biovest”), on the one hand, and LV ADMINISTRATIVE SERVICES, INC., a Delaware corporation, as administrative and collateral agent for the Lenders (the “Agent”), LAURUS MASTER FUND, LTD. (IN LIQUIDATION)
(“Laurus”), VALENS U.S. SPV I, LLC, VALENS OFFSHORE SPV I, LTD., VALENS OFFSHORE SPV II, CORP. and PSOURCE STRUCTURED DEBT LIMITED (collectively, the “Prepetition Lenders” and together with the Agent, the
“Creditor Parties”), on the other hand. 
 RECITALS 

WHEREAS, pursuant to that certain letter agreement dated as of March 19, 2007 (the “March 2007
Agreement”), by and among Biovest, the Biovest Subsidiaries, Accentia and Laurus, Biovest and AutovaxID granted to Laurus a non-cancelable royalty equal to three percent (3%) of world-wide Net Sales (defined as gross receipts from the
world-wide sales of AutovaxIDTM Instruments less any rebates, returns and discounts) of AutovaxIDTM Instruments (defined as the automated cell and biologic production instrument known as AutovaxIDTM) for a period of five years commencing
on May 31, 2007 (the “AutovaxID Royalty”); 
 WHEREAS, pursuant to that certain
Term Loan and Security Agreement (the “Security Agreement”) dated as of November 17, 2010, by and among Biovest, the Lenders party thereto and the Agent, the parties hereto, in consideration for the acceptance by certain of the
Prepetition Lenders of the allowed secured claims against Biovest as provided therein, have agreed, among other things, to the termination of the AutovaxID Royalty; and 

WHEREAS, pursuant to the terms and conditions of the Security Agreement and the Confirmed Plan, the parties hereto
hereby desire to terminate the AutovaxID Royalty effective as of the date of this Agreement. 
 NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 
 1.        Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Security Agreement. 

2.        The parties hereto agree that the above Recitals are true and correct
in all respects. 
 3.        The parties hereto hereby consent to the
termination of the AutovaxID Royalty (and all of the rights and obligations created thereunder) effective as of the date of this Agreement. 
 4.        Each of the Creditor Parties hereby acknowledges and agrees that it shall have no claims of any nature whatsoever against Biovest, AutovaxID or Accentia
as a result of the termination of the AutovaxID Royalty. 

  
 -1-

 5.        This Agreement shall be
binding upon the parties hereto and their respective successors and assigns. The parties hereto agree that this Agreement is fully and adequately supported by consideration, is fair and reasonable, and that they have had the opportunity to discuss
this matter with counsel of their choice. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall be deemed to constitute one agreement. It is understood and agreed that
if facsimile copies of this Agreement bearing facsimile signatures are exchanged between the parties hereto, such copies shall in all respects have the same weight, force and legal effect and shall be fully as valid, binding, and enforceable as if
such signed facsimile copies were original documents bearing original signature. 

6.        THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED, INTERPRETED AND
ENFORCED ACCORDING TO, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICT OF LAWS PROVISIONS THEREOF. ANY ACTION BROUGHT CONCERNING THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT SHALL BE BROUGHT ONLY IN THE STATE
COURTS OF NEW YORK OR IN THE FEDERAL COURTS LOCATED IN THE STATE OF NEW YORK. The prevailing party shall be entitled to recover from the other party its reasonable attorneys’ fees and costs. Wherever possible each provision of this
Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective to the extent of such
prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. 

[remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first
above written. 
  

			
	AUTOVAXID, INC.

			
		
	By:	 	 /s/ David Moser

	Name:	 	David Moser
	Title:	 	Secretary

  

			
	BIOVEST INTERNATIONAL, INC.
		
	By:	 	 /s/ David Moser

	Name:	 	David Moser
	Title:	 	Secretary

  

			
	LV ADMINISTRATIVE SERVICES, INC.

			
		
	By:	 	 /s/ Patrick
Regan

			
	Name:	 	Patrick Regan

			
	Title:	 	Authorized Signatory

  

			
	 LAURUS MASTER FUND, LTD. (IN
 LIQUIDATION)

			
		
	By:	 	 /s/ Russell
Smith

			
	Name:	 	Russell Smith

			
	Title:	 	Joint Official Liquidator (with no personal
	liability)

  

			
	VALENS U.S. SPV I, LLC

			
		
	By:	 	 /s/ Patrick
Regan

			
	Name:	 	Patrick Regan

			
	Title:	 	Authorized Signatory

  

			
	 VALENS OFFSHORE SPV I,
LTD.

			
		
	By:	 	 /s/ Patrick
Regan

			
	Name:	 	Patrick Regan

			
	Title:	 	Authorized Signatory

  

			
	VALENS OFFSHORE SPV II, CORP.

			
		
	By:	 	 /s/ Patrick
Regan

			
	Name:	 	Patrick Regan

			
	Title:	 	Authorized Signatory

  

			
	PSOURCE STRUCTURED DEBT LIMITED
	By:	 	PSource Capital Ltd, It’s Investment Consultant
		
	By:	 	 /s/ Charles
Lews

			
	Name:	 	Charles Lews

			
	Title:	 	Associate Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]